Potentiation of a topoisomerase i inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase l/ll clinical trial

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2479-2487

  Daud, Adil I ^b   Dawson, Jana ^a   Deconti, Ronald C ^a   Bicaku, Elona ^a   Marchion, Douglas ^a   Bastien, Sem ^a   Hausheer III, Frederick A ^c   Lush, Richard ^a   Neuger, Anthony ^a   Sullivan, Daniel M ^a   Munster, Pamela N ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Bio Numerik Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KARENITECIN; TOPOTECAN; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATAXIA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMET ASSAY; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DNA STRAND BREAKAGE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN CELL; LEUKOPENIA; MALE; MELANOMA; METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HISTONES; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; MIDDLE AGED; SKIN NEOPLASMS; VALPROIC ACID;

EID: 65249131145     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1931     Document Type: Article

References (29)

1. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006;12:2366-70s.
2. Daud A, Valkov N, Centeno B, et al. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 2005;11: 3009-16.
3. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92:223-37.
4. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Exp Opin Invest Drugs 2007;16:659-78.
5. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7:583-98.
6. Dokmanovic M, Clarke C, Marks PA. Histone deace- tylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981 -9.
7. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-93.
8. Gurvich N,Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64: 1079-86.
9. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61:8492-7.
10. Marks PA, Richon VM, Rifkind RA. Histone deace- tylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92: 1210-6.
11. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291 -300.
12. Tsai SC, Valkov N, Yang WM, Gump J, SullivanD, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000;26: 349-53.
13. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4:1993-2000.
14. Munster P, Marchion D, Bicaku E,et al. PhaseI trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-85.
15. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409: 581 -9.
16. Marchion DC, Bicaku E,TurnerJG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ. Clin Cancer Res 2005;11:8467-75.
17. Singh NP, McCoy MT,Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175: 184-91.
18. Singh NP, Danner DB,Tice RR, McCoy MT, Collins GD, Schneider EL. Abundant alkali-sensitive sites in DNA of human and mouse sperm. Exp Cell Res 1989; 184:461 -70.
19. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004;26:249-61.
20. Smith JA, Hausheer F, Newman RA, Madden TL. Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine. J Chromatogr B Biomed Sci Appl 2001;759:117-24.
21. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry on Bioanalytical Method Validation. Federal Register 2001;66 28526 docket no. 98D-1195.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
23. Bedikian AY, Millward M, Pehamberger H, et al. Bcl- 2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24: 4738-45.
24. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
25. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25.
26. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
27. Atkins ME, Lee S, Flahert L, J S, Sondak V, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon α- 2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated Intergroup study. Chicago (IL): ASCO; 2003.
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon α- 2b. J Clin Oncol 1999;17:968-75.
29. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster. PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005;65:3815-22.